Any place left for induction chemotherapy for locally advanced head and neck squamous cell carcinoma?
Fiche publication
Date publication
avril 2018
Journal
Anti-cancer drugs
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BOREL Christian, Dr BURGY Mickaël
Tous les auteurs :
Burgy M, Leblanc J, Borel C
Lien Pubmed
Résumé
The issue of induction chemotherapy (ICT) interest in locoregionally advanced squamous cell cancer of the head and neck is a real epic that has been carried out over four phase III studies: PARADIGM, DECIDE, NCT01086826 and lastly the conclusive GORTEC 2007-02. With no significant benefit in overall survival of ICT, followed by concurrent chemoradiation over the standard chemoradiotherapy alone, in three of these studies, and a significant number of treatment-related deaths with the standard regimen docetaxel, cisplatin, and fluorouracil, ICT is no longer a hot topic. However, this strategy might still be useful in the aim of limiting the metastatic extension affecting up to 30% of patients: ICT is systematically associated with a reduced metastatic relapse even though the survival effect is never statistically significant when compared directly with concomitant radiochemotherapy. This review summarizes the major studies with their limits and discusses how the ICT could improve the patients' prognosis in the future.
Référence
Anticancer Drugs. 2018 Apr;29(4):287-294